ArticleBiomarkers in medicine2025
Prognostic significance of combined serum immunological HER2 and ERα36 biomarkers in estrogen receptor-positive breast cancer subtypes.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most common cancer among women, with rising incidence and mortality rates, posing clinical treatment challenges.
objectiveTo analyze the prognostic significance of serum immune HER2 and ERα36 biomarkers in estrogen receptor-positive breast cancer subtypes.
methodsSixty-one estrogen receptor-positive breast cancer cases from Fourth Hospital of Hebei Medical University (2016-2023) were analyzed. The qPCR was used to detect the expression level of ERα36 mRNA in the sample, and ELISA was used to detect the expression of HER2 in the sample. Associations between biomarker expression, clinicopathological features, and prognosis were evaluated.
resultsERα36 mRNA expression was higher in breast cancer tissues than in adjacent tissues (
conclusionERα36 and HER2 are valuable prognostic biomarkers, with their co-expression linked to increased lymph node metastasis and poorer survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.